 Paul Christine
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 11 | 2025 | 509 | 3.590 |
Why?
| | Opiate Substitution Treatment | 7 | 2025 | 151 | 2.840 |
Why?
| | Buprenorphine | 5 | 2024 | 169 | 1.850 |
Why?
| | Residence Characteristics | 4 | 2018 | 349 | 1.310 |
Why?
| | Narcotic Antagonists | 4 | 2025 | 179 | 1.200 |
Why?
| | Methadone | 3 | 2025 | 99 | 1.120 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 2 | 2025 | 11 | 1.110 |
Why?
| | Naltrexone | 2 | 2025 | 97 | 1.020 |
Why?
| | Substance Withdrawal Syndrome | 6 | 2025 | 178 | 0.980 |
Why?
| | Environment Design | 2 | 2015 | 27 | 0.960 |
Why?
| | Analgesics, Opioid | 8 | 2025 | 992 | 0.950 |
Why?
| | Medicaid | 3 | 2024 | 433 | 0.930 |
Why?
| | Insurance Coverage | 2 | 2024 | 229 | 0.930 |
Why?
| | Food Supply | 2 | 2015 | 80 | 0.910 |
Why?
| | Social Environment | 2 | 2015 | 295 | 0.850 |
Why?
| | Comparative Effectiveness Research | 1 | 2024 | 150 | 0.810 |
Why?
| | Insurance, Health | 1 | 2024 | 280 | 0.750 |
Why?
| | Fentanyl | 4 | 2025 | 94 | 0.700 |
Why?
| | Motor Activity | 2 | 2015 | 717 | 0.680 |
Why?
| | Substance-Related Disorders | 3 | 2024 | 1069 | 0.580 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2017 | 2518 | 0.550 |
Why?
| | Massachusetts | 3 | 2024 | 171 | 0.480 |
Why?
| | Housing | 1 | 2016 | 146 | 0.480 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1301 | 0.480 |
Why?
| | Social Class | 1 | 2017 | 281 | 0.470 |
Why?
| | Health Transition | 1 | 2014 | 7 | 0.460 |
Why?
| | Economic Development | 1 | 2014 | 3 | 0.460 |
Why?
| | Middle Aged | 20 | 2025 | 33228 | 0.420 |
Why?
| | Atherosclerosis | 1 | 2017 | 415 | 0.400 |
Why?
| | Blood Pressure | 3 | 2025 | 1774 | 0.380 |
Why?
| | Drug Overdose | 3 | 2025 | 345 | 0.370 |
Why?
| | Group Processes | 1 | 2012 | 62 | 0.370 |
Why?
| | Body Mass Index | 3 | 2018 | 2375 | 0.370 |
Why?
| | Social Identification | 1 | 2012 | 67 | 0.350 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5423 | 0.350 |
Why?
| | Overweight | 1 | 2014 | 557 | 0.320 |
Why?
| | Male | 23 | 2025 | 67309 | 0.320 |
Why?
| | Humans | 33 | 2025 | 136764 | 0.310 |
Why?
| | Patient Participation | 1 | 2013 | 418 | 0.310 |
Why?
| | Education, Medical | 1 | 2012 | 260 | 0.300 |
Why?
| | Longitudinal Studies | 4 | 2024 | 2829 | 0.300 |
Why?
| | Female | 24 | 2025 | 72787 | 0.300 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 738 | 0.290 |
Why?
| | Adult | 16 | 2025 | 37630 | 0.290 |
Why?
| | Students, Medical | 1 | 2012 | 339 | 0.270 |
Why?
| | United States | 8 | 2025 | 14691 | 0.270 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1282 | 0.260 |
Why?
| | Blood Glucose | 1 | 2016 | 2181 | 0.260 |
Why?
| | Delayed-Action Preparations | 2 | 2025 | 180 | 0.260 |
Why?
| | Smoking | 4 | 2018 | 1620 | 0.250 |
Why?
| | Decision Making | 1 | 2013 | 898 | 0.240 |
Why?
| | Xylazine | 1 | 2025 | 14 | 0.240 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2025 | 24 | 0.230 |
Why?
| | Heroin | 1 | 2025 | 31 | 0.230 |
Why?
| | Cohort Studies | 4 | 2025 | 5701 | 0.230 |
Why?
| | Heroin Dependence | 1 | 2025 | 33 | 0.230 |
Why?
| | Kentucky | 1 | 2024 | 39 | 0.220 |
Why?
| | Mifepristone | 1 | 2024 | 64 | 0.220 |
Why?
| | Amphetamine-Related Disorders | 1 | 2024 | 40 | 0.220 |
Why?
| | Diazepam | 1 | 2024 | 35 | 0.220 |
Why?
| | Interrupted Time Series Analysis | 1 | 2024 | 68 | 0.220 |
Why?
| | New York | 1 | 2024 | 126 | 0.220 |
Why?
| | Ohio | 1 | 2024 | 152 | 0.220 |
Why?
| | Hospitals, Urban | 1 | 2024 | 133 | 0.220 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 116 | 0.210 |
Why?
| | Substance Abuse, Intravenous | 1 | 2024 | 114 | 0.200 |
Why?
| | Benzodiazepines | 1 | 2024 | 153 | 0.200 |
Why?
| | Central Nervous System Stimulants | 1 | 2024 | 161 | 0.200 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1261 | 0.200 |
Why?
| | Naloxone | 1 | 2024 | 121 | 0.200 |
Why?
| | Young Adult | 8 | 2025 | 13129 | 0.200 |
Why?
| | Abortion, Induced | 1 | 2024 | 105 | 0.190 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2024 | 213 | 0.190 |
Why?
| | Obesity | 1 | 2014 | 2982 | 0.180 |
Why?
| | Endocarditis, Bacterial | 1 | 2021 | 41 | 0.170 |
Why?
| | Aged, 80 and over | 4 | 2016 | 7585 | 0.170 |
Why?
| | Patient-Centered Care | 1 | 2025 | 522 | 0.160 |
Why?
| | Adolescent | 8 | 2025 | 21382 | 0.160 |
Why?
| | Aged | 7 | 2021 | 23794 | 0.160 |
Why?
| | Economic Recession | 1 | 2018 | 4 | 0.150 |
Why?
| | Unemployment | 1 | 2018 | 43 | 0.150 |
Why?
| | Colorado | 2 | 2025 | 4518 | 0.150 |
Why?
| | Risk Factors | 3 | 2017 | 10326 | 0.140 |
Why?
| | Argentina | 2 | 2014 | 26 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1127 | 0.140 |
Why?
| | Prevalence | 3 | 2024 | 2711 | 0.120 |
Why?
| | Patient Care Team | 1 | 2021 | 626 | 0.120 |
Why?
| | Smoke-Free Policy | 1 | 2015 | 12 | 0.120 |
Why?
| | Geographic Information Systems | 1 | 2015 | 44 | 0.120 |
Why?
| | Public Opinion | 1 | 2015 | 65 | 0.120 |
Why?
| | Pandemics | 1 | 2023 | 1613 | 0.110 |
Why?
| | Behavior | 1 | 2015 | 90 | 0.110 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2016 | 102 | 0.110 |
Why?
| | Models, Psychological | 1 | 2016 | 302 | 0.110 |
Why?
| | China | 1 | 2015 | 216 | 0.110 |
Why?
| | Alcohol Drinking | 2 | 2018 | 820 | 0.110 |
Why?
| | Spatio-Temporal Analysis | 1 | 2014 | 34 | 0.110 |
Why?
| | Prospective Studies | 2 | 2017 | 7572 | 0.110 |
Why?
| | Incidence | 2 | 2024 | 2792 | 0.110 |
Why?
| | Analysis of Variance | 1 | 2016 | 1316 | 0.110 |
Why?
| | Amnion | 1 | 2013 | 28 | 0.100 |
Why?
| | Nutrition Surveys | 1 | 2014 | 266 | 0.100 |
Why?
| | Health Behavior | 1 | 2018 | 756 | 0.100 |
Why?
| | Potassium Channels, Calcium-Activated | 1 | 2012 | 11 | 0.100 |
Why?
| | Smoking Cessation | 1 | 2016 | 436 | 0.100 |
Why?
| | Mental Health | 1 | 2018 | 716 | 0.090 |
Why?
| | Premature Birth | 2 | 2013 | 331 | 0.090 |
Why?
| | Diffusion of Innovation | 1 | 2012 | 98 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 119 | 0.090 |
Why?
| | Science | 1 | 2012 | 53 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2013 | 375 | 0.090 |
Why?
| | Physician's Role | 1 | 2012 | 211 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 349 | 0.080 |
Why?
| | HIV Infections | 1 | 2024 | 2828 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 2060 | 0.070 |
Why?
| | Physician-Patient Relations | 1 | 2013 | 548 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3432 | 0.070 |
Why?
| | DNA Methylation | 1 | 2013 | 640 | 0.070 |
Why?
| | Communication | 1 | 2013 | 875 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2104 | 0.060 |
Why?
| | Philadelphia | 1 | 2024 | 49 | 0.060 |
Why?
| | Hostility | 1 | 2024 | 15 | 0.060 |
Why?
| | Hospitalization | 2 | 2024 | 2183 | 0.060 |
Why?
| | Minnesota | 1 | 2023 | 162 | 0.050 |
Why?
| | Health Surveys | 1 | 2025 | 513 | 0.050 |
Why?
| | Heart Rate | 1 | 2025 | 820 | 0.040 |
Why?
| | Health Policy | 1 | 2024 | 385 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2025 | 800 | 0.040 |
Why?
| | Propensity Score | 1 | 2021 | 289 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2024 | 780 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1462 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 685 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2025 | 15504 | 0.030 |
Why?
| | Pregnancy | 2 | 2024 | 6728 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2024 | 978 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2021 | 901 | 0.030 |
Why?
| | Educational Status | 1 | 2018 | 470 | 0.030 |
Why?
| | Mexico | 1 | 2015 | 225 | 0.030 |
Why?
| | Lipids | 1 | 2018 | 665 | 0.030 |
Why?
| | Receptors, Oxytocin | 1 | 2013 | 23 | 0.030 |
Why?
| | Indians, South American | 1 | 2012 | 25 | 0.020 |
Why?
| | CpG Islands | 1 | 2013 | 157 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2015 | 261 | 0.020 |
Why?
| | Labor, Obstetric | 1 | 2013 | 61 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 194 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2046 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2013 | 134 | 0.020 |
Why?
| | Genetic Loci | 1 | 2013 | 288 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 200 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2013 | 6033 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 403 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 766 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 10744 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2018 | 1097 | 0.020 |
Why?
| | Gestational Age | 1 | 2013 | 902 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 659 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1395 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2013 | 1249 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 657 | 0.020 |
Why?
| | Fetus | 1 | 2012 | 806 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1914 | 0.020 |
Why?
| | Exercise | 1 | 2018 | 2043 | 0.020 |
Why?
| | Placenta | 1 | 2013 | 749 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1772 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2184 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2412 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5742 | 0.010 |
Why?
|
|
Christine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|